FAvipiravir and HydroxyChloroquine Combination Therapy

NACompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

January 26, 2021

Study Completion Date

April 26, 2021

Conditions
COVID19
Interventions
COMBINATION_PRODUCT

Favipiravir and Hydroxychloroquine

"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."

Trial Locations (8)

11426

King Abdulaziz Medical City, National Guard Health Affairs, Riyadh

Unknown

King Abdulaziz Hospital - Al Ahsa, Hasa

AlMadina General Hospital, Al Madīnah

Al-Qatif Central Hospital, Al Qaţīf

Imam Abdulrahman Al Faisal Hospital - Dammam, Dammam

King Abdulaziz Medical City, Jeddah

King Abdulaziz Hospital - Makkah, Mecca

Imam Abdulrahman Alfaisal Hospital, Riyadh

All Listed Sponsors
lead

King Abdullah International Medical Research Center

OTHER

NCT04392973 - FAvipiravir and HydroxyChloroquine Combination Therapy | Biotech Hunter | Biotech Hunter